One of the most interesting aspects of a newly published study of bevacizumab (Avastin) for older patients with advanced non-small cell lung cancer (NSCLC) is the abstract’s conclusion: “Adding bevacizumab to carboplatin and paclitaxel chemotherapy

Avastin for Lung Cancer
Posted April 17, 2012 by